Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-11-02

Clinical Trial Update: Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis [Phase 2]

View source ↗

Summary

Phase 2 study updates for LY3556050 in osteoarthritis as part of a chronic pain master protocol; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LY3556050 (LY3556050)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Osteoarthritis | Phase 2 | Status: COMPLETED | Results posted: 2023-11-02